Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MANT3_ASC in Chronic Low Back Pain
NCT05011474Phase 2Unknown
- Start
- Apr 2021
- Primary completion
- Jan 2022
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of autologous adipose-derived mesenchymal stem cell spheroid pretreated with matrillin 3 in lumbar degenerative disc disease (LDDD). Primary endpoints: Adverse reaction and serious adverse reaction evaluation, Laboratory inspection and 4 more. Status: unknown.
02
Drugs
autologous adipose-derived mesenchymal stem cell spheroid pretreated with matrillin 3
03
Conditions
lumbar degenerative disc disease (LDDD)
Beyond the preview
Go deeper on NCT05011474.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05011474.